Jump to content

Edward F. Fritsch

Add links
From Wikipedia, the free encyclopedia

Edward Francis Fritsch (born June 1, 1950) is a scientist in the field of molecular biology and cancer immunology.[1]

Fritsch completed his PhD at the University of Wisconsin–Madison under Howard Temin.[1][2] His thesis was titled, "Synthesis and structure of avian retrovirus DNA".[1] As a postdoctoral fellow under Tom Maniatis at California Institute of Technology, Fritsch entered the field of recombinant DNA by constructing the first complete library of the human genome along with Dr. Richard Lawn.[3][4] In 1982, Fritsch, Joe Sambrook, and Maniatis wrote Molecular Cloning: A Laboratory Manual, which was considered "omnipresent in Molecular Biology laboratories and [...] utilized to the point where it is frequently referred to as ‘The Bible’.”[5] Fritsch helped initiate and for four years co-taught the widely successful Cold Spring Harbor course on Molecular Cloning.[6] Fritsch's work in molecular cloning continued at Genetics Institute, acquired by Wyeth in 1992, where he worked on the discovery and production of therapeutic recombinant proteins, including the cloning of the erythropoietin (EPO) gene.[7]

Fritsch then joined Phylos, Inc. to utilize a in vitro, directed-evolution technology to discover new protein therapeutics, eventually becoming Chief Scientific Officer[8]

He later worked with Cathy Wu and Nir Hacohen at the Dana–Farber Cancer Institute and the Broad Institute of MIT and Harvard.[9] There he led the development of NeoVax, a first-in-class personalized neoantigen cancer vaccine through IND approval and successful execution of two clinical trials[10][11]

In 2015, he co-founded Neon Therapeutics, Inc.[12] (acquired by BioNTech in 2020 for $67M),[13] as Chief Technology Officer to work on personalizedcancer vaccines.[14] In 2019, he left Neon to re-join the Dana–Farber Cancer Institute and the Broad Institute to continue work on the subject.

References[edit]

  1. ^ a b c "Synthesis and structure of avian retrovirus DNA". ProQuest. ProQuest. Retrieved 9 November 2023.
  2. ^ "About us". UCIR. Understanding Cancer Immunotherapy Research. Retrieved 9 November 2023.
  3. ^ Claiborn, Kathryn (2012-10-01). "Gene pioneers: Donald Brown and Thomas Maniatis win the 2012 Lasker~Koshland Special Achievement Award in Medical Science". The Journal of Clinical Investigation. 122 (10): 3383–3386. doi:10.1172/JCI66476. ISSN 0021-9738. PMC 3461937. PMID 23193577.
  4. ^ Lawn, Richard M.; Fritsch, Edward F.; Parker, Richard C.; Blake, Geoffrey; Maniatis, Tom (1978-12-01). "The isolation and characterization of linked δ- and β-globin genes from a cloned library of human DNA". Cell. 15 (4): 1157–1174. doi:10.1016/0092-8674(78)90043-0. ISSN 0092-8674. PMID 728996. S2CID 54279445.
  5. ^ "Molecular Cloning (AKA Maniatis, AKA The Bible) at 25". Bench Marks. 2007-10-22. Retrieved 2020-08-19.
  6. ^ Clark, Jess. "Recipes for Recombining DNA. A History of Molecular Cloning: A Laboratory Manual". The Recipes Project. Retrieved 2020-08-19.
  7. ^ Jacobs, Kenneth; Shoemaker, Charles; Rudersdorf, Richard; Neill, Suzanne D.; Kaufman, Randal J.; Mufson, Allan; Seehra, Jasbir; Jones, Simon S.; Hewick, Rodney; Fritsch, Edward F.; Kawakita, Makoto (February 1985). "Isolation and characterization of genomic and cDNA clones of human erythropoietin". Nature. 313 (6005): 806–810. Bibcode:1985Natur.313..806J. doi:10.1038/313806a0. ISSN 1476-4687. PMID 3838366. S2CID 4340224.
  8. ^ Fritsch, Edward. "Protein Scaffolds for Novel Anti-Cancer Agents". {{cite journal}}: Cite journal requires |journal= (help)
  9. ^ Hacohen, Nir; Fritsch, Edward F.; Carter, Todd A.; Lander, Eric S.; Wu, Catherine J. (2013-07-01). "Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines". Cancer Immunology Research. 1 (1): 11–15. doi:10.1158/2326-6066.CIR-13-0022. ISSN 2326-6066. PMC 4033902. PMID 24777245.
  10. ^ Ott, Patrick A.; Hu, Zhuting; et al. (July 2017). "An immunogenic personal neoantigen vaccine for patients with melanoma". Nature. 547 (7662): 217–221. Bibcode:2017Natur.547..217O. doi:10.1038/nature22991. ISSN 1476-4687. PMC 5577644. PMID 28678778.
  11. ^ Keskin, Derin B.; Anandappa, Annabelle J.; et al. (January 2019). "Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial". Nature. 565 (7738): 234–239. doi:10.1038/s41586-018-0792-9. hdl:1721.1/125401. ISSN 1476-4687. PMC 6546179. PMID 30568305. S2CID 216713646.
  12. ^ "Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies". FiercePharma. Retrieved 2020-08-19.
  13. ^ "BioNTech to acquire Neon to strengthen global leadership position in T cell therapies | BioNTech". investors.biontech.de. Retrieved 2020-08-19.
  14. ^ "Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2017". BioSpace. Retrieved 2020-08-19.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Edward_F._Fritsch&oldid=1184275260"